Maggot therapy reimbursement is no longer as simple as it was once claimed to be. Yet, neither is it as universally difficult as some commentors suggest it is. The truth lies somewhere in between, and depends very much on circumstances.

Reimbursement procedures and prospects depend on the Patient, their wound type, the
reason for doing the treatment, and the specific insurance coverage that they may or may not have. Reimbursement prospects also depend just as much on the care provider, their documentation, and the type of facility where the procedure was performed. Some insurers are very clear about their willingness to reimburse for maggot therapy,
and make their policies and procedures public. Others have no public policy, or no policy at all. But the primary reason that reimbursement is not a straightforward process is that there is no procedure code (CPT) for maggot therapy, and no product code (HCPCS Level 2) for medicinal maggots or their dressings. Reimbursement requests are generally
submitted using these universal codes.

Many third party payers will recommend submitting a reimbursement request using the general debridement code CPT 97602. That makes a lot of sense for them, especially because CPT 97602 designates a procedure specifically defined as non-reimbursable. In other words, if that code is used, the insurer does not need to pay for the procedure nor the supplies, based on the very definition of that code.


Our advice is generally as follows: If a patient has insurance or some other 3 rd party payer, that payer should be contacted in advance and asked to pay for the therapy. This process is called “Prior Authorization” (PA), and is generally well-defined by all payers. For routine situations, an answer is available within a couple days. Emergency situations are generally answered within 24 hours. Once you receive assurance to pay for the procedure, you no longer need to worry about reimbursement.

Prior Authorization is not always granted upon the first request. Afterall, the person reviewing the request is not a health care professional, and will be looking primarily for diagnostic codes, CPT codes and HCPCS Level 2 codes (which do not exist specifically for maggot therapy). Additionally, many payers operate with the understanding that the more they pay for health care the less they will keep in profits (in the case of private insurers) or in reserve (as in the case for government- or non-profit-run programs). That is simply the reality of the health care financing structure that currently exists in the U.S. So what do you do if you receive a denial to the Prior Authorization request (which is quite likely)? You submit an appeal.

In our experience, PA Appeals are your best opportunity to obtain reimbursement. PA appeals are reviewed by a healthcare professional. As such, you (or more commonly the prescriber) have/has the opportunity to have your case heard by a medical professional. What is generally required to win an appeal is a proper reason for the procedure (“approved indication”), and evidence that other methods were unsuccessful or contra indicated. If you add to that some scientific evidence (even many health care professionals may not be well-acquainted with the scientific literature supporting maggot therapy) and a cost estimate comparing likely costs of MDT vs likely costs of alternatives (or actual costs of prior treatment efforts), the wisdom of paying for maggot therapy (especially compared to surgery or amputation) become evident. If you need assistance in navigating the reimbursement arena or preparing a strong PA appeal, contact us. If you are a coding or reimbursement professional and would like to improve this advice or assist patients with questions, please contact us.